Osteoporosis :: Reclast receives US regulatory approval as first and only once-yearly treatment for women with postmenopausal osteoporosis
Reclast? (zoledronic acid) Injection has been approved by the US Food and Drug Administration as the first and only once-yearly medicine for postmenopausal osteoporosis, offering an important new approach to the treatment of a bone disease affecting eight million women in the US.